Page last updated: 2024-12-05

medazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Medazepam is a benzodiazepine derivative with anxiolytic, sedative, and muscle relaxant properties. It was first synthesized in the 1960s and was marketed under the brand name Nobrium in several countries. Medazepam is a prodrug, meaning it is converted into an active metabolite, desmethyldiazepam, in the body. This metabolite is responsible for most of the drug's effects. It is metabolized by the liver and is eliminated in urine. The drug has a relatively long duration of action, with effects lasting up to 24 hours. Medazepam is primarily used to treat anxiety disorders, insomnia, and muscle spasms. However, its use has declined in recent years due to concerns about addiction and side effects. Research on medazepam has focused on its pharmacological properties, therapeutic effects, and potential risks. Studies have investigated its efficacy in treating anxiety, insomnia, and muscle spasms, as well as its potential for abuse and dependence. While it has shown promise in some areas, the use of medazepam is often limited by its long duration of action and potential side effects. Due to its long half-life and the availability of safer alternatives, it is rarely prescribed today.'

Medazepam: A benzodiazepine derivative used in the treatment of anxiety. It has sedative, muscle relaxant, and anticonvulsant properties. One of its metabolites is DIAZEPAM and one of its excretion products is OXAZEPAM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4041
CHEMBL ID28333
CHEBI ID31807
SCHEMBL ID18472
MeSH IDM0013187

Synonyms (79)

Synonym
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1h-[1,4]benzodiazepine
azepamide
stratium
brn 0407983
aensius
benaon
dea no. 2836
medazepamum [inn-latin]
navizil
7-chloro-2,3-dihydro-1-methyl-5-phenyl-3h-1,4-benzodiazepine
enobrin
medaurin
nobraksin
rb 252
7-chloro-2,3-dihydro-1-methyl-5-phenyl-1h-1,4-benzodiazepine
medazepam [inn:ban:jan]
nobral
1h-1,4-benzodiazepine, 2,3-dihydro-7-chloro-1-methyl-5-phenyl-
einecs 220-783-4
2,3-dihydro-7-chloro-1-methyl-5-phenyl-1h-1,4-benzodiazepine
narsis
lerisum
nivelton
nobrium hcl
1h-1,4-benzodiazepine, 7-chloro-2,3-dihydro-1-methyl-5-phenyl-
medazepam
rb-252
rudotel
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepine
nobrium hydrochloride
ansius
resmit
1h-1,4-benzodiazepine, 7-chloro-2, 3-dihydro-1-methyl-5-phenyl, monohydrochloride
1h-1,4-benzodiazepine, 7-chloro-2,3-dihydro-1-methyl-5-phenyl-, monohydrochloride
2898-12-6
nobrium
7-chloro-2, 3-dihydro-1-methyl-5-phenyl-1h-1,4-benzodiazepine, hydrochloride
ansilan
nsc169896
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
7-chloro-2,3-dihydro-1-methyl-5-phenyl-1h-1, 4-benzodiazepine monohydrochloride
D01292
pamnace (tn)
medazepam (jp17/inn)
NCGC00164523-01
CHEMBL28333 ,
pamnace
AKOS002254761
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepine
bdbm50021058
medazepamum
p0j3387w3s ,
unii-p0j3387w3s
5-23-09-00037 (beilstein handbook reference)
tox21_113107
dtxsid1048708 ,
cas-2898-12-6
dtxcid8028634
STL257370
medazepam [mi]
medazepam [mart.]
medazepam [inn]
medazepam [jan]
medazepam [who-dd]
SCHEMBL18472
1-methyl-5-phenyl-7-chloro-2,3-dihydro-1h-1,4-benzodiazepine
megasedan (salt/mix)
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepine #
esmail (salt/mix)
medazepol (salt/mix)
mezapam
elbrus (salt/mix)
psiquium
diepin (salt/mix)
CHEBI:31807
Q572796
DB13437
(z)-7-chloro-1-methyl-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepine
medazepam, 1mg/ml in acetonitrile

Research Excerpts

Overview

Medazepam is a less hard (i.e., less stable) compound than nordazepAM.

ExcerptReferenceRelevance
"Medazepam is a less hard (i.e., less stable) compound than nordazepam."( Electronic properties of neuroleptics: ionization energies of benzodiazepines.
Alparone, A; Millefiori, S, 2011
)
1.09

Treatment

ExcerptReferenceRelevance
"2. Medazepam treatment caused significant decrease of muscarinic receptor binding affinity (Kd) and of the receptor binding capacity (Bmax) in the brain structures studied."( Effect of the combination of the benzodiazepine tranquilizer medazepam and the nootropic agent meclofenoxate on the activity of rat brain muscarinic receptors.
Petkov, VD; Popova, JS, 1990
)
1.03

Pharmacokinetics

ExcerptReferenceRelevance
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
" Potential pharmacokinetic determinants of duration of drug action are dose, lipid solubility and elimination half-life."( Introduction to the pharmacokinetics and pharmacodynamics of benzodiazepines.
McKenzie, SG, 1983
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Twenty anxious patients were treated with medazepam, diazepam, chlordiazepoxide, amylobarbitone and placebo, each given in flexible dosage for 2-4 weeks."( Plasma concentrations of benzodiazepines.
Bond, AJ; Hailey, DM; Lader, MH, 1977
)
0.52
" The mean self-adjusted dosage was 16."( Medazepam and the driving ability of anxious patients.
Moore, NC, 1977
)
1.7
" These findings and other results of pharmacokinetic research have clinical implications in terms of dosage schedules, drug accumulation during long-term therapy, antianxiety therapy in the elderly, drug interactions, pharmacotherapy in specific disease states, and the influence of route of administration on drug action."( Clinical implications of benzodiazepine pharmacokinetics.
Greenblatt, DJ; Shader, RI, 1977
)
0.26
" The dose-response curves for CCK8 were shifted in parallel to the right by 10(-6) to 10(-5) M of the three benzodiazepines, although the maximum response to CCK8 was depressed by higher concentrations."( Cholecystokinin antagonism by benzodiazepines in the contractile response of the isolated guinea-pig gallbladder.
Kubota, K; Matsuda, I; Sugaya, K; Sunagane, N; Uruno, T, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624172
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency21.13170.000723.06741,258.9301AID743085
Cellular tumor antigen p53Homo sapiens (human)Potency5.95570.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki0.52800.00020.561410.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki0.52800.00020.635210.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.52800.00020.621710.0000AID40970
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki0.52800.00020.675810.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.52800.00020.646910.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki0.52800.00020.671210.0000AID40970
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.52800.00020.557710.0000AID40970
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki0.52800.00020.640310.0000AID40970
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.52800.00020.570810.0000AID40970
GABA theta subunitRattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki0.52800.00020.656110.0000AID40970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Translocator proteinRattus norvegicus (Norway rat)Kd0.01000.00060.82834.0000AID39918
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd0.01000.00012.29338.5114AID39918
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
GABA theta subunitRattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Kd0.01000.00020.56294.4668AID39918
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1130728Toxicity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID1130724Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for muscle relaxing activity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID1130720Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of maximum electro shock-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID194133ED50 value was reported as log1/C, which is the concentration that caused fourfold increase of lever pressing in 50% of rats for the punished schedule; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID1130718Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of pentylenetetrazole-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID1130726Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for behavioral activity in po dosed albino Swiss-Webster mouse by fighting test1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID11307291-Octanol-aqueous phosphate buffer partition coefficient, log P of the compound at pH 7.351979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID194135ED50 value was reported as log1/C, which is the concentration that would decrease to a half the lever pressing in 50% of rats for the non punished schedule; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID194131ED50 value was reported as log1/C, which is the concentration required to reduce locomotor activity by 50% in rats1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID23479Partition coefficient (logP)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Rm values and structure-activity relationship of benzodiazepines.
AID40970In vitro binding affinity against benzodiazepine receptor using [3H]diazepam as radioligand1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.
AID226432Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1130721Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for anticonvulsant activity in po dosed albino Swiss-Webster mouse assessed as reduction of minimum electro shock-induced seizure1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID1130727Potency index, ratio of chlordiazepoxide ED50 to compound ED50 for hypnotic activity in po dosed albino Swiss-Webster mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis of some carbon-3 substituted 1,4-benzodiazepin-2-ones and their central nervous system effects.
AID39918Binding affinity constant for peripheral (mitochondrial) Benzodiazepine receptor1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines toward mitochondrial benzodiazepine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (111)

TimeframeStudies, This Drug (%)All Drugs %
pre-199086 (77.48)18.7374
1990's10 (9.01)18.2507
2000's8 (7.21)29.6817
2010's5 (4.50)24.3611
2020's2 (1.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.10 (24.57)
Research Supply Index4.95 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index104.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (12.00%)5.53%
Reviews3 (2.40%)6.00%
Case Studies5 (4.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (81.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study [NCT01984931]Phase 345 participants (Anticipated)Interventional2013-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]